Bio-Genesis product seizure
This article was originally published in The Tan Sheet
Executive Summary
FDA seized two Bio-Genesis products, Latero-Flora and Flora-Balance, at the company's San Marcos, Calif. headquarters and San Bernardino, Calif. manufacturing facility on April 22. FDA tests revealed that the products in liquid form were contaminated with Pseudomonas, Flavobacterium and Bacillus bacteria, which the agency said "can cause severe or fatal infections in people with weakened immune systems." The products, which FDA said are promoted especially to chemotherapy, organ transplant, AIDS and long-term antibiotic patients, are marketed to aid "in resolving many immuno-suppressed conditions" and relieve symptoms of chronic fatigue syndrome, hay fever, athlete's foot and tonsillitis. The agency said it is still investigating the case and does not know how much of the nationally marketed products are still on store shelves
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning